GOLDSTEIN DOV A MD 4

What Happened

• Dov A. Goldstein, MD, Chief Financial Officer of BioAge Labs, was reported as acquiring a 110,000-share derivative award on 2026-02-17. The reported acquisition shows $0.00 paid (no cash exchanged) and is recorded as an award/grant of a derivative security (an option or similar equity award), not a stock sale or open-market purchase.

Key Details

• Transaction date: 2026-02-17; Filing date: 2026-02-19 (timely).
• Consideration: $0.00 (award/grant of a derivative security).
• Number of shares/units involved: 110,000 (derivative award).
• Shares owned after the transaction: not specified in the provided filing details.
• Footnote: The award vests 1/48th each month (monthly over 4 years). The first tranche vested on Feb 1, 2026; subsequent tranches vest monthly thereafter, contingent on continued service.
• No immediate sale or exercise reported — this is a compensation grant, not a realized cash transaction.

Context

• This appears to be an equity compensation grant (stock options or RSUs) that will vest monthly over four years. Because the filing shows an award at $0.00 and does not report an exercise or sale, there is no immediate cash value realized and no direct buy/sell market signal. The award vests only with continued service, which is standard for executive compensation.